NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Benitec Biopharma Inc. (BNTC) Stock Analysis

Benitec Biopharma Inc. (BNTC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BNTC

$12.68

+$0.24 (+1.93%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BNTC with… →

BNTC Key Statistics

As of Sep 4, 2026
Trading
Open
$12.33
Previous Close
$12.44
Day's Range
12.33–12.83
52-Week Range
9.85–16.76
Volume
45.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.27
Valuation
Market Cap
$435.61M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.95
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$37.92M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
34.35M
1-Year Return
−9.43%
Dividend and dates
Earnings Date
September 22, 2026estimated
Avg Volume
141.82K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BNTC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−5.86%
2025+6.65%
2024+291.02%
2023+11.76%
2022−93.51%
2021−12.67%
2020−60.78%
2019−66.00%
2018−49.27%
2017+93.46%
2016 (partial year)−11.51%

As of September 4, 2026.

BNTC Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$37.92M—
2024$0.00−$21.75M—
2023$75.00K−$19.56M−26082.7%
2022$73.00K−$18.21M−24942.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$41.77M−$37.92M—
2024$0.00—−$22.49M−$21.75M—
2023$75.00K$75.00K−$19.08M−$19.56M−26082.7%
2022$73.00K$64.00K−$17.85M−$18.21M−24942.5%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

BNTC Valuation vs Biotechnology Median

Median of 656 stocks
MetricBNTCBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Benitec Biopharma Inc. (BNTC) carries a market capitalisation of $435.61M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 19.

The 52-week range on file runs from $9.85 to $16.76. The most recent close on file for BNTC is $12.68, dated September 4, 2026. That is +$0.24 (+1.93%) against the previous close. The latest close sits 28.73% above that 52-week low.

Financial Health

In fiscal 2025, Benitec Biopharma Inc. reported revenue of $0.00. The same year closed with a net loss of $37.92M. The reported profit margin is 0%. Trailing earnings per share are −0.95.

Across the 4 fiscal years on file, revenue moves from $73.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.27. Annualized volatility over the trailing 10 years is 131.57%. The trailing one-year price return is −9.43%. Across 10 years the annualized return works out at −29.36%.

Growth & Income

No dividend is on file for BNTC.

2026 is still running; the price is −5.86% year to date. Across the complete calendar years on file, 2024 returned +291.02% and 2022 returned −93.51%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Benitec Biopharma Inc. (BNTC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Benitec Biopharma Inc. BNTC $435.61M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Benitec Biopharma Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Benitec Biopharma Inc.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Visit website →